CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,475 enrolled
Drug / intervention
Villalta phone score > or = to 5 +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03054727
NCT03054727N/ACompleted

Long Term Natural History of PTS and Other Adverse Outcomes After Venous Thromboembolism in the Optimev Study (SPOT)

Association des Médecins Vasculaires Hospitaliers·observational·Posted Feb 16, 2017·Updated Jan 23, 2023

In Brief

An observational study evaluating Villalta phone score > or = to 5 and Villalta phone score < 5 for Post Thrombotic Syndrome and 2 related conditions. Completed, enrolled 2,475 participants across 1 site.

Detailed Summary

Post-thrombotic syndrome (PTS) is a frequent and burdensome complication of deep-vein thrombosis (DVT). In the absence of curative treatment of established PTS, its management is based on the prevention of its occurrence thanks to anticoagulants and compression stockings. So far, predictors of disabling PTS are unknown precluding from optimally selecting patients for invasive (early thrombus removal) or innovative/expensive treatments. In addition, little is known on the incidence of PTS in the very long-term. Objectives: To assess, 12 years after a symptomatic venous thromboembolic (VTE) event, Primary objective: incidence and severity of PTS after a lower limb DVT. Main Secondary objectives: 1. Incidence and severity of PTS according to VTE initial presentation (isolated distal DVT, isolated proximal DVT, PE + DVT). 2. Incidence and risk factors of disabling PTS Methods: Very long-term follow-up (12 years) of patients recruited in the large, multicentre, prospective, observational OPTIMEV study for a suspicion of VTE confirmed or ruled out with objective tests (Clinical Trials NCT00670540). All patients with a DVT, an isolated PE and a random selection of controls (VTE - patients without any history of VTE after the 3 years of follow-up) will first benefit from a phone-PTS assessment. Those patients presenting at least a mild venous insufficiency and a selection of controls will undergo a clinical follow-up visit with clinical and Compleat Ultra Sound (CUS) assessment of PTS/venous insufficiency and an assessment of quality of life. Perspectives: Improving our knowledge of PTS' incidence and predictors and of the impact of usual treatment. Better selecting patients eligible for invasive/innovative/expensive preventative procedures.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesFrance

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 16, 2017
Enrollment StartJul 11, 2017
Primary CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 9.4 years ago

Interventions

Villalta phone score > or = to 5other

Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \> or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency. All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination.

Villalta phone score < 5other

Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \< 5, will don't have a clinical follow up. All patients will have self administered-questionnaires.